



CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Effective Date 5/15/2009
Next Review Date 5/15/2010
Coverage Policy Number 4014

Subject Alefacept (Amevive®)

Table of Contents

Coverage Policy	1
General Background	1
Coding/Billing Information	3
References	3
Policy History	6

Hyperlink to Related Coverage Policies

Enbrel®
Humira®
Remicade®

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans as well as benefit plans formerly administered by Great-West Healthcare. Please note, the terms of a participant's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a participant's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a participant's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable group benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2009 CIGNA

Coverage Policy

CIGNA HealthCare covers alefacept (Amevive®) as medically necessary for the treatment of moderate-to-severe chronic plaque psoriasis in individuals 18 years of age and older who are candidates for or have previously received EITHER of the following:

- systemic therapy (e.g., methotrexate, cyclosporin, soriatane)
- phototherapy [narrow or broad band ultraviolet B (UVB), or psoralen plus ultraviolet A (PUVA)]

Note: Coverage may be approved for up to 12 weeks. Coverage may be approved for re-treatment **ONCE** as long as the total lymphocyte and CD4+ T cell counts are within normal range and a minimum of 12 weeks has passed since the last course of therapy. Data on re-treatment beyond two cycles are limited.

General Background

U.S. Food and Drug Administration (FDA) Approved Indication

Alefacept is a biological agent labeled for the treatment of moderate-to-severe chronic plaque psoriasis for adult patients who are candidates for systemic therapy or phototherapy.

FDA Recommended Dosing

The recommended dose of alefacept is 15 mg given once weekly as an intramuscular (IM) injection. The recommended regimen is a course of 12 weekly injections. Retreatment with an additional 12-week course may be initiated provided that CD4+ T lymphocyte counts are within the normal range, and a minimum of a 12-week interval has passed since the previous course of treatment. The CD4+ T lymphocyte counts of patients receiving alefacept should be monitored before initiating dosing and every two weeks throughout the course of the 12-week dosing regimen. If CD4+ T lymphocyte counts are below 250 cells/ μ L, alefacept dosing should be withheld and weekly monitoring instituted. Alefacept should be discontinued if the counts remain below 250 cells/ μ L for one month.

In clinical practice, the severity of a patient's psoriasis is evaluated by combining the objective assessment (e.g. body surface area (BSA) of involvement, disease location, thickness) and subjective assessment of the physical, financial, and emotional impact of the disease on the patient's life. This subjective assessment is combined with the physician's global assessment of psoriasis to determine psoriasis severity and appropriate therapy. The National Psoriasis Foundation Medical Board (Pariser, et al., 2007) recommends two-tiered system that categorizes patients based on treatment plans as candidates for localized therapy or for systemic therapy and/or phototherapy. Localized therapy, which includes topical treatments and excimer laser treatments, is recommended for patients with psoriasis that affects less than 5% BSA. Appropriate therapies include, but are not restricted to, topical corticosteroids, topical cholecalciferol analogs, combinations of these 2, topical retinoids, tar preparations, anthralin, keratolytics, and excimer (UV-B) laser treatments. In general, the effects of topical therapy should become evident within the first two to three weeks of use. Clearing of scale is usually observed first, followed by flattening of the treated plaques. Resolution of erythema may take six to eight weeks. Systemic therapy and/or phototherapy, which includes broad and narrowband phototherapy, photochemotherapy (PUVA), systemic agents, and biologics, is recommended for patients with psoriasis affecting greater than 5% BSA, for those with less than 5% BSA affected in vulnerable areas, such as the face, genitals, hands or feet, and for other forms of psoriasis, including but not limited to erythrodermic, pustular, and guttate. In addition, patients with limited affected areas and inadequate response to localized therapy or impairment in physical or mental functioning should also be considered candidates for systemic and/or phototherapy treatment.

The American Academy of Dermatology (AAD) published a consensus statement (Callen, et al., 2003) on psoriasis therapies. The document is intended to be used as a guide to the evaluation and treatments of psoriasis until evidence based guidelines are developed. Within this document, the authors state that BSA should not generally be used to determine which therapy to select; moderate and severe disease overlap and individuals with limited disease can be considered moderate for the purposes of selecting a therapy. Topical therapies are recommended for limited plaque disease. For moderate to severe disease, the AAD recommends phototherapy, targeted phototherapy, narrowband UVB, photochemotherapy with psoralen and UVA light (PUVA), topicals and systemic treatments.

Alefacept is fusion protein that prevents the activation of T lymphocytes involved in the pathogenesis of psoriasis. In placebo-controlled trials, alefacept demonstrated improvement in psoriasis-specific indices when compared to baseline values and patients taking placebo. Alefacept is effective when given either intravenously or intramuscularly. The first course of therapy with alefacept is attributed to the greatest clinical improvement and a second course is well-tolerated and increases efficacy. Clinical response is related to reductions in lymphocyte counts. Repeat courses of alefacept show equal to greater benefit and may increase duration of response; however, data concerning usage beyond two treatment cycles are limited. Rebounds in psoriasis after completion of therapy have not been reported with alefacept, indicating it acts as remittive therapy rather than an immunosuppressive.

Two controlled clinical studies included 1060 patients who had chronic (i.e., duration of one year or longer) plaque psoriasis with involvement of at least 10% of the body surface area and who were candidates for or had previously received systemic therapy or phototherapy. In these studies, 14 or 21% of patients receiving alefacept 7.5 mg intravenous (IV) or 15 mg intramuscular (IM) once weekly, respectively, achieved a response (i.e., reduction in Psoriasis Area and Severity Index [PASI] score of at least 75% compared with baseline) at two weeks following a 12-week course of therapy, compared with 4–5% of patients receiving placebo. An additional 7–11% of patients receiving alefacept achieved a response (i.e., reduction in PASI score of at least 75% compared with baseline) beyond two weeks post-treatment. Response rate at two weeks following a second 12-week course of IV or IM alefacept therapy was 26%, or 30%, respectively.

In both clinical studies, onset of response (reduction in PASI score of at least 50% compared with baseline) reportedly was observed 60 days after initiation of alefacept therapy. The median duration of response (maintenance of 75% or greater reduction in PASI score) after a 12-week course of therapy with alefacept 7.5 mg IV or 15 mg IM once weekly was 3.5 or two months, respectively. However, patients who achieved at least a 75% reduction in baseline PASI score during or after a single 12-week course of IV alefacept therapy maintained a 50% or greater reduction in PASI score for a median of seven months. The duration of response appeared to be longer after a second course of IV alefacept therapy; however, median duration of response was not determined, since the study was terminated after one year.

Alefacept should not be used concurrently with other immunosuppressive agents or in patients currently receiving phototherapy. The concomitant use of low-potency topical corticosteroids was permitted during clinical studies.

Alefacept is supplied in either a carton containing four doses, or in a carton containing one dose. Each four-dose pack contains four 15-mg single-use vials of alefacept. Each single-dose contains one 15-mg single-use vial of alefacept.

Coding/Billing Information

Note: This section is not in use.

References

1. Amevive (alefacept). Deerfield, IL: Astellas Pharma US, Inc. March 2009.
2. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. *BMJ* 2000;320:963-7.
3. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. *BMJ* 2000;320:963-7.
4. Bandy V. Alefacept: A T-cell-specific immunosuppressant to treat moderate to severe plaque psoriasis. *Formulary*. July 2002;37:346-353.
5. Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, Paller AS, Pariser DM, Weinblatt M, Zimmerman G; AAD. AAD consensus statement on psoriasis therapies. *Am Acad Dermatol*. 2003 Nov;49(5):897-9.
6. Christophers E. Psoriasis: epidemiology and clinical spectrum. *Clin Exp Dermatol*. Jun 2001;26(4):314-320.
7. Christophers E. Targeting T-cell subsets to achieve remission. *J Eur Acad Dermatol Venereol*. Jul 2003;17 Suppl 2:6-11.
8. Cooper JC, Morgan G, Harding S, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. *Eur J Immunol*. Mar 2003;33(3):666-675.
9. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. *J Immunol*. May 1 2002;168(9):4462-4471.
10. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. *N Engl J Med*. Jul 26 2001;345(4):248-255.

11. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. *Am J Clin Dermatol.* 2003;4(2):131-139.
12. Finlay AY, Salek MS, Haney J, For The Alefacept Clinical Study Group F. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. *Dermatology.* 2003;206(4):307-315.
13. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. *J Am Acad Dermatol.* Jun 2003;48(6):829-835.
14. Granstein RD. New treatments for psoriasis. *N Engl J Med.* Jul 26 2001;345(4):284-287.
15. Karrer S, Eholzer C, Ackermann G, Landthaler M, Szeimies RM. Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches. *Dermatology.* 2001;202(2):108-115.
16. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. *Dermatologica* 1991;183:269-74.
17. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. *J Am Acad Dermatol.* Jul 1999;41(1):51-59.
18. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. *Arthritis Rheum.* Oct 2002;46(10):2776-2784.
19. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. *Arch Dermatol.* Mar 2001;137(3):280-284.
20. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. *Br J Dermatol.* Apr 2003;148(4):784-788.
21. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. *J Am Acad Dermatol.* Dec 2002;47(6):821-833.
22. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. *J Eur Acad Dermatol Venereol.* Jul 2003;17 Suppl 2:17-24.
23. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol.* Jan 2002;46(1):1-23; quiz 23-26.
24. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. *J Am Acad Dermatol.* Nov 2001;45(5):649-661; quiz 662-644.
25. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. *Arch Dermatol.* Jun 2003;139(6):719-727.
26. Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. *Int J Dermatol.* Mar 2003;42(3):224-230.
27. Luba KM, Stulberg DL. Chronic plaque psoriasis. *Am Fam Physician.* 2006;73(4):636-44.
28. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. *Br J Dermatol* 2002;146:351-64.

29. Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. *Eur Dermatol*. Mar-Apr 2003;13(2):117-123.
30. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. *J Eur Acad Dermatol Venereol*. Jul 2003;17 Suppl 2:12-16.
31. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. *Arch Dermatol*. 2007 Feb;143(2):239-42.
32. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. *Am J Health Syst Pharm*. Apr 1 2000;57(7):645-659; quiz 660-641.
33. The U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Amevive (alefacept). Available at: <http://www.fda.gov/cder/foi/label/2003/alefbio013003LB.htm>. Accessed on February 1, 2008.

Policy History

<u>Pre-Merger Organizations</u>	<u>Last Review Date</u>	<u>Policy Number</u>	<u>Title</u>
CIGNA HealthCare Great-West Healthcare	5/30/2008	4014	Alefacept (Amevive®)

“CIGNA” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. and Great-West Healthcare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Connecticut General Life Insurance Company has acquired the business of Great-West Healthcare from Great-West Life & Annuity Insurance Company (GWLA). Certain products continue to be provided by GWLA (Life, Accident and Disability, and Excess Loss). GWLA is not licensed to do business in New York. In New York, these products are sold by GWLA's subsidiary, First Great-West Life & Annuity Insurance Company, White Plains, N.Y.